Modified arabinoxylan from rice bran, MGN-3/biobran, sensitizes metastatic breast cancer cells to paclitaxel in vitro.

Abstract

BACKGROUND:

There is an increased interest in alternative treatments that reduce the toxicity of chemotherapy by lowering the drug concentration, whilst maintaining potency against cancer cells. Previous studies have demonstrated that arabinoxylan from rice bran, MGN-3/Biobran, sensitizes human breast cancer cells (BCC) to daunorubicin (DNR). In the present study, we further evaluated the ability of MGN-3 to sensitize cells to another chemotherapy agent, paclitaxel.

MATERIALS AND METHODS:

Non-metastatic MCF-7 (human BCC) and metastatic 4T1 (murine BCC) cells were cultured with different concentrations of paclitaxel in the presence or absence of MGN-3. Cell survival, DNA damage, and cell proliferation were examined.

RESULTS:

MGN-3 increased the susceptibility of both types of cancer cells to paclitaxel by over 100-fold. Mechanistically, MGN-3 works synergistically with paclitaxel by causing DNA damage, enhancing apoptosis, and inhibiting cell proliferation in 4T1 cells.

CONCLUSION:

Our data demonstrate that MGN-3 is an effective chemosensitizer and may represent a novel adjuvant for the treatment of metastatic breast cancer.

• Authors: Mamdooh Ghoneum, Nariman K Badr El-Din, Doaa A Ali, Mai Alaa El-Dein
• Journal: Anticancer research (Anticancer Res) Vol. 34 Issue 1 Pg. 81-7 (Jan 2014) ISSN: 1791-7530 [Electronic] Greece
• PMID: 24403447 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents, Phytogenic
• Xylans
• polysaccharide MGN3
• Paclitaxel

Topics

• Antineoplastic Agents, Phytogenic (pharmacology)
• Apoptosis (drug effects)
• Breast Neoplasms (drug therapy, metabolism, pathology)
• Cell Proliferation (drug effects)
• DNA Damage (drug effects)
• Drug Resistance, Neoplasm (drug effects)
• Female
• Flow Cytometry
• Humans
• In Vitro Techniques
• Oryza (chemistry)
• Paclitaxel (pharmacology)
• Tumor Cells, Cultured
• Xylans (pharmacology)